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Monocyte–macrophage ferric reductase activity is inhibited by iron and
stimulated by cellular differentiation
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The enzyme ferric reductase catalyses the reduction of Fe(III) as
a prerequisite to its transportation across the cell membrane.
Duodenal mucosal biopsies from iron overloaded patients with
genetic haemochromatosis (GH) have increased ferric reductase
activity and iron absorption compared with controls, yet the GH
mucosa is iron deficient. A similar GH-related iron deficiency is
also seen in macrophages. The aim of this study was to investigate
whether macrophage ferric reductase activity is altered in GH,
and to determine ferric reductase activity in monocytes and
differentiated macrophages. The erythroleukaemic K562 cell line
was studied as a clonal reference cell line. The basal K562 ferric
reductase activity is characteristic of a membrane bound enzyme,
being both temperature and protease sensitive. Ferric reductase
activity was also demonstrated in human leucocyte, monocyte
and macrophage preparations. Assays of K562 and macrophage
INTRODUCTION
Iron is of vital importance in all living organisms, being an
essential cofactor of enzymes involved in respiration, cell rep-
lication and electron shuttling. The homoeostasis of iron is
maintained primarily by its absorption in the duodenum and the
proximal region of the jejunum [1]. Normally the daily loss of
iron (1–2 mg) is matched by absorption from the diet. This fine
balance between iron excretion and absorption is lost in genetic
haemochromatosis (GH). This autosomal recessive disease leads
to increased absorption of iron from the diet despite increasing
body iron stores. Iron is deposited in the parenchymal tissue of
the liver, pancreas, heart and other tissues. If untreated, the iron
overload eventually leads to tissue damage. The prevalence of
GH in Europeans is approximately 1 in 300, which is higher than
the combined prevalence of cystic fibrosis, phenylketonuria and
Duchenne muscular dystrophy [2–4].
Recently a candidate gene for haemochromatosis (HFE) was
identified [5]. In the United Kingdom, 91% of GH patients were
found to be homozygous for a single mutation of HFE, Cys#)#Tyr
(Cys#)#!Tyr) [6]. Although the metabolic role of the HFE
protein is not fully understood, recent advances support a role in
the regulation of iron absorption [7–10].
Abnormalities of iron metabolism in the intestine, liver and
macrophages have all been implicated in the pathogenesis of GH
[11–13]. In the haemochromatotic macrophage, despite the
elevation of serum iron and transferrin saturation, concentrations
of iron are minimal until late in the disease [14]. This is in
contrast with transfusional siderosis, where there is progressive
Abbreviation used: GH, genetic haemochromatosis.
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cell supernatants confirmed that the ferric reductase activity was
not due to a secreted factor. Assay of ferric reductase in
normalized-iron and iron-enriched (100 lM ferric citrate) con-
ditions showed no significant difference between Cys#)#Tyr
(Cys#)#!Tyr) homozygous GH macrophages and Cys#)#-
Tyr negative control activities (P" 0.05). However, a 900%
increase in ferric reductase activity was observed during mono-
cyte to macrophage differentiation (P! 0.05), possibly reflecting
the co-ordinate up-regulation of iron metabolism in these cells.
The demonstration of approx. 25% activity after macrophage
differentiation at high free-iron concentrations compared with
‘normalized’ iron is consistent with repression of human ferric
reductase activity by iron. The identification of the human
ferric reductase gene and its protein will ultimately provide insight
into its regulation and role in mammalian iron metabolism.
accumulation of iron by the macrophage. This difference exists
despite similar increases in serum-ferritin levels [15]. Cultured
GH monocytes also have elevated levels of ferritin release, and
abnormal kinetics of iron release, compared with control mono-
cytes [16,17].
The uptake of ‘ free ’ iron provided in the form of ferric citrate
by mononuclear cells has been established [18,19]. Both free iron
uptake and ferric reductase activity have been shown to be
increased in duodenal biopsies from haemochromatosis patients
as compared with controls [20,21].
Ferric reductase activity has been described in both prokaryotic
and eukaryotic cells, including Escherichia coli, Saccharomyces
cereisiae, mouse, rat, rabbit and human duodenum, rat liver
endosomes, rabbit reticulocytes and various cultured cell lines
[21–24]. Its conservation across species indicates a functional
role. The S. cereisiae gene for ferric reductase (FRE1) has been
cloned and sequenced [22,23]. The ferric iron uptake mechanism
in the yeast, S. cereisiae, utilizes the ferric reductase enzyme to
reduce Fe(III) before absorption. The ferrous Fe(II) iron is
transported through the membrane, and is thought to be re-
oxidized back to Fe(III) as it passes through the membrane. The
human homologue of FRE1 has yet to be cloned. However,
partial purification of human ferric reductase from both human
Hutu 80 duodenal adenocarcinoma cells and human duodenal
microvillus membranes has shown that the activity is NADH-
dependent and the protein is membrane bound [24].
We demonstrate ferric reductase activity in the K562 human
erythroleukaemic cell line and primary cultures of human leu-
cocytes, monocytes and macrophages. We report ferric
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reductase activity in cells from GH patients compared with




Ten male patients were investigated: five GH and five control
patients with no family history of iron disorders. The diagnosis
of GH was made from clinical and biochemical data and
confirmed by a hepatic iron index " 1.9 and}or removal of " 5 g
of iron during initial phlebotomies [3,6,25]. The groups were age
matched: GH, 49‡17.4 years ; control, 55‡5.3 years,
(mean‡S.D.).
Mutation analysis
The Cys#)#Tyr and His’$Asp mutations of the haemochromatosis
gene, HFE, were determined by PCR and restriction enzyme
digestion [6]. All haemochromatosis patients studied were homo-
zygous for the Cys#)#Tyr mutation and negative for His’$Asp.
Two controls carried a single copy of His’$Asp; all controls were
negative for Cys#)#Tyr.
Cell culture
White blood cells were extracted from peripheral blood using
Lymphoprep2 (Nycomed). Monocytes were enriched by their
adherence to plastic. Adherent monocytes were cultured for 14
days for in itro differentiation to macrophages [26]. Cell numbers
were determined using a haemocytometer and by fluorescence
activated cell sorter analysis (Coulter EpicXL). Cell viability was
confirmed by Trypan Blue exclusion (" 95%). The purity of the
primary cell cultures was assessed by morphological criteria
(Leishmanns stain) and CD14 fluorescence-activated cell sorter
analysis ; typical purities were 80% for monocytes and 95% for
macrophages. The clonal erythroleukaemic cell line K562 was
included in all experiments as an internal control. Cells were
cultured at 37 °C either in conditions of ‘normalized’ iron
(24 lM iron, transferrin saturation 30%), or in normalized
medium supplemented with 100 lM ferric citrate, to reflect the
elevated in io concentrations of serum iron and free iron of a
heavily iron-loaded haemochromatotic [27,28]. The 100 lM
ferric citrate solutionwas freshly prepared as amixture containing
100 lM ferric chloride and 150 lM sodium citrate, as described
previously [29]. Cell cultures supplemented with ferric citrate
were protected from light and fresh medium was substituted after
7 days. In addition to the protection from light and chelation by
citrate, stability of Fe(III) was also conferred by the RPMI 1640
culture medium itself, which contains many other chelating
agents at high concentrations. These include amino acids, sugars,
vitamins, bicarbonate and phosphate, which also prevent the
hydrolytic polymerization of iron [30]. The amino acids and
glucose alone provide an additional 150-fold molar excess of
chelating agent over iron [30].
Ferric reductase assay
Cells were harvested, rinsed, then incubated at a concentration of
2‹10’ cells}ml in 200 ll of oxygenated physiological buffer





10 mM d-glucose in 16 mM Hepes}NaOH, pH 7.4) in 96-well
tissue culture plates at 37 °C. The reaction was started by the
addition of 100 lM Fe(III), as a ferric chelate of nitrilotriacetate
in a 1:2 ratio (Fe:nitrilotriacetate), and ferrozine (1 mM). The
reaction was performed at 37 °C. The rate of reaction was
determined spectrophotometrically at 562 nm by measuring the
reduction of the yellow Fe(III) to the purple coloured stable
Fe(II)–ferrozine complex [21].
RESULTS
Preliminary experiments investigated the characteristics of the
ferric reductase activity of the clonal control K562 erythro-
leukaemic cell line. In each experiment the rate of ferric reductase
activity was determined by linear regression analysis of at least
three time courses ; each individual time point was performed in
duplicate. All time courses were linear for at least 60 min. After
mild trypsinization, ferric reductase activity was decreased to
38.7% of the control (Table 1). Heating the cells to 65 °C for
5 min prior to assay decreased activity to 26.7% of the control.
When the assay was performed at 10 °C, 17% of the control
activity was observed. These observations were consistent with
the assay of a membrane bound protein. When K562 and
macrophage cell-free supernatants were taken for determining
reductase activity at the end of the incubation period, only
background levels of reductase activity were detected (Table 1).
This indicated that the activity was not due to a soluble, released
Table 1 Human ferric reductase activity has the characteristics of a
membrane bound enzyme
The cells were subjected to various treatments and then ferric reductase activity was measured
and expressed as a percentage of K562 control activity at 37 °C (mean‡S.D. ; n fl 3).  The
ferric reductase activity for the control K562 cells was 6.93 nmol of Fe[min−1[(109 cells)−1,
where 1 lM ferric iron gave an absorbance of approx. 0.03 at 562 nm. , The reaction was
performed in the absence of ferrozine, cells were removed by centrifugation, and the activity in
the supernatant was determined after the addition of ferrozine. Activities are compared with the
control ; **P! 0.01 (Student’s t-test).
Cell type Treatment Ferric reductase activity (%)
K562 0.1 mg/ml trypsin, 37 °C, 60 min 38.7‡1.5**
K562 65 °C, 5 min 26.7‡1.5**
K562 Assay performed at 10 °C 17.0‡1.7**
K562 Supernatant activity 0.33‡0.58**
Macrophage Supernatant activity 0.02‡0.02**
Table 2 Ferric reductase activities
Activities are shown for lymphocytes, monocytes and macrophages from classical Cys282Tyr
homozygous GH patients and Cys282Tyr negative control patients. Statistical probabilities were
assessed using the Student’s t-test. There was a significant increase in activity with
differentiation of the monocytes to macrophages, for both GH (*) and control () preparations
(P!0.05 in both cases). N, normalized-iron culture medium (see the Materials and methods
section) ; 100 lM, iron loaded (additional 100 lM ferric citrate in normalized-iron medium).
Ferric reductase activity
[nmol of Fe[min−1[(109 cells)−1]



































































factor. These observations indicate that ferric reductase is a
membrane bound enzyme.
Investigation of primary cultures of lymphocytes, monocytes and
macrophages demonstrated ferric reductase activity in these blood-
derived cells (Table 2). No significant difference (P! 0.05) was
observed between GH (Cys#)#Tyr homozygous) and control
(Cys#)#Tyr negative) in either lymphocyte, monocyte or macrophage
preparations. However, ferric reductase activity of macrophages
was approx. 900% of the monocyte activity, for both GH and
control preparations, when cultured in normalized iron.
When K562 cells were cultured in normal or high iron (100 lM
ferric citrate) concentrations, no difference in ferric reductase
activity was observed (P" 0.05; Table 2)
When macrophages were cultured in media containing 100 lM
ferric citrate for 2 weeks, no significant difference (P" 0.05) was
observed between GH and the control. However, the ferric
reductase activity of both GH and control macrophages cultured
under these conditions was approx. 25% of the activity when
grown at normalized iron concentrations (P! 0.05; Table 2).
DISCUSSION
The ferric reductase activity of human K562 cells was dem-
onstrated to have the characteristics of a membrane bound
enzyme and was not attributable to the secretion of reducing
factors. There was no significant difference in the reductase
activity between GH and controls for leucocyte, monocyte or
macrophage preparations. This was observed under both normal-
ized iron conditions and in the presence of 100 lM ferric citrate.
Ferric reductase activity of differentiated macrophages was
approx. 900% that of monocyte activity (P! 0.05). This increase
most likely reflects the co-ordinated up-regulation of the proteins
of iron metabolism during the transition into macrophages [31].
Macrophage ferric reductase activity was decreased when cul-
tured in 100 lM ferric citrate compared with that in normalized
iron. From these results it would appear that macrophage ferric
reductase activity may be determined by external free-iron
concentrations during macrophage differentiation. Macrophage
ferric reductase activity was down-regulated by increased free-
iron concentration.
This control of ferric reductase activity could contribute to the
low levels of iron observed in the haemochromatotic macrophage.
As haemochromatotic macrophages differentiate in high free-
iron conditions in io, their ferric reductase activities may be
decreased according to the amount of free iron present. Future
studies could address this issue by isolating differentiated macro-
phages from GH and control human subjects, and measuring the
activity of the in io differentiated cells. The clonal reference cell
line K562 did not show modulation of ferric reductase activity by
iron. The K562 cell line originates from an erythroid cell clone
derived from a patient with myeloid leukaemia in acute blast
crisis [32]. The lack of modulation of K562 ferric reductase
activity by iron may reflect either the erythroid lineage or
changes in the clonal expansion of this cell line. The identification
of the human ferric reductase gene will ultimately establish
whether it is transcriptionally repressed by iron, as in S. cereisiae.
Future studies will elucidate whether ferric reductase plays a role
in the apparent iron deficiency of macrophages in GH.
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